| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rare Diseases | 3 | 2020 | 360 | 0.840 |
Why?
|
| Genes, erbB-2 | 5 | 2007 | 228 | 0.590 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2020 | 3397 | 0.570 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2020 | 1335 | 0.540 |
Why?
|
| Receptor, ErbB-2 | 6 | 2021 | 2648 | 0.440 |
Why?
|
| Biomarkers, Tumor | 9 | 2021 | 10698 | 0.400 |
Why?
|
| Triple Negative Breast Neoplasms | 5 | 2021 | 1347 | 0.370 |
Why?
|
| Gene Amplification | 5 | 2007 | 769 | 0.360 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 3 | 2022 | 527 | 0.310 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2019 | 1010 | 0.280 |
Why?
|
| Breast Neoplasms | 13 | 2021 | 16186 | 0.270 |
Why?
|
| Neoplasms | 4 | 2020 | 15849 | 0.210 |
Why?
|
| Cell Cycle Proteins | 3 | 2021 | 2125 | 0.210 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2021 | 530 | 0.200 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2015 | 1233 | 0.200 |
Why?
|
| Discoidin Domain Receptor 1 | 1 | 2021 | 15 | 0.190 |
Why?
|
| Oxadiazoles | 1 | 2021 | 60 | 0.190 |
Why?
|
| Oxidative Phosphorylation | 1 | 2021 | 267 | 0.170 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2021 | 323 | 0.170 |
Why?
|
| PHD Zinc Fingers | 1 | 2019 | 4 | 0.170 |
Why?
|
| Anilides | 1 | 2021 | 295 | 0.160 |
Why?
|
| Metabolome | 1 | 2021 | 355 | 0.160 |
Why?
|
| Benzimidazoles | 1 | 2022 | 441 | 0.160 |
Why?
|
| Histone Code | 1 | 2019 | 86 | 0.160 |
Why?
|
| In Situ Hybridization, Fluorescence | 7 | 2011 | 2314 | 0.150 |
Why?
|
| Heterografts | 1 | 2020 | 745 | 0.150 |
Why?
|
| Prognosis | 11 | 2021 | 22458 | 0.140 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2019 | 192 | 0.140 |
Why?
|
| Observer Variation | 2 | 2016 | 723 | 0.140 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2019 | 244 | 0.140 |
Why?
|
| Biopsy | 2 | 2020 | 3545 | 0.140 |
Why?
|
| Homeodomain Proteins | 2 | 2012 | 1135 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2021 | 10349 | 0.130 |
Why?
|
| Piperidines | 1 | 2021 | 1089 | 0.130 |
Why?
|
| beta Catenin | 1 | 2019 | 690 | 0.130 |
Why?
|
| Phthalazines | 1 | 2017 | 262 | 0.130 |
Why?
|
| BRCA2 Protein | 1 | 2017 | 370 | 0.130 |
Why?
|
| Disease Progression | 4 | 2020 | 6893 | 0.120 |
Why?
|
| Receptors, Estrogen | 2 | 2021 | 2264 | 0.120 |
Why?
|
| Mitotic Index | 1 | 2015 | 166 | 0.120 |
Why?
|
| Pathology, Clinical | 1 | 2016 | 155 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 1053 | 0.120 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 516 | 0.120 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2021 | 2618 | 0.120 |
Why?
|
| Female | 24 | 2022 | 148509 | 0.120 |
Why?
|
| Pyridines | 1 | 2021 | 1311 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2021 | 2093 | 0.110 |
Why?
|
| Aged, 80 and over | 10 | 2020 | 30941 | 0.110 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2019 | 879 | 0.110 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2012 | 1885 | 0.110 |
Why?
|
| Cell Proliferation | 4 | 2021 | 7294 | 0.110 |
Why?
|
| Ki-67 Antigen | 1 | 2015 | 685 | 0.110 |
Why?
|
| Carcinogenesis | 1 | 2019 | 1030 | 0.100 |
Why?
|
| Tissue Array Analysis | 3 | 2015 | 759 | 0.100 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 1057 | 0.100 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 7461 | 0.100 |
Why?
|
| Transcription Factor RelA | 1 | 2012 | 186 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2022 | 3920 | 0.100 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2019 | 1654 | 0.100 |
Why?
|
| Histones | 1 | 2019 | 1510 | 0.100 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2020 | 5568 | 0.090 |
Why?
|
| Salvage Therapy | 1 | 2019 | 2117 | 0.090 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 1894 | 0.090 |
Why?
|
| Aged | 13 | 2020 | 73161 | 0.090 |
Why?
|
| Colorectal Neoplasms | 2 | 2022 | 3657 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 2019 | 1380 | 0.090 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2011 | 195 | 0.090 |
Why?
|
| Humans | 27 | 2022 | 270947 | 0.090 |
Why?
|
| Breast | 2 | 2015 | 1364 | 0.090 |
Why?
|
| Receptors, Androgen | 1 | 2015 | 922 | 0.090 |
Why?
|
| Middle Aged | 13 | 2020 | 90021 | 0.080 |
Why?
|
| Mice, Nude | 3 | 2022 | 4360 | 0.080 |
Why?
|
| Neoplasm Proteins | 2 | 2019 | 3349 | 0.080 |
Why?
|
| Adult | 12 | 2020 | 81555 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2021 | 4956 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 3657 | 0.080 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 1260 | 0.080 |
Why?
|
| Cell Line, Tumor | 6 | 2021 | 14864 | 0.080 |
Why?
|
| Carcinoma, Lobular | 1 | 2012 | 617 | 0.080 |
Why?
|
| Estradiol | 1 | 2011 | 885 | 0.080 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 5411 | 0.070 |
Why?
|
| Brachytherapy | 1 | 2014 | 1005 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 2 | 2007 | 1215 | 0.070 |
Why?
|
| Apoptosis | 3 | 2021 | 7847 | 0.070 |
Why?
|
| Proto-Oncogenes | 1 | 2006 | 208 | 0.070 |
Why?
|
| Gene Deletion | 1 | 2011 | 1482 | 0.070 |
Why?
|
| Immunohistochemistry | 4 | 2015 | 7813 | 0.060 |
Why?
|
| Lymphatic Metastasis | 4 | 2019 | 4968 | 0.060 |
Why?
|
| Mice | 6 | 2022 | 35992 | 0.060 |
Why?
|
| Neoplasm Staging | 7 | 2019 | 13976 | 0.060 |
Why?
|
| False Negative Reactions | 1 | 2004 | 293 | 0.060 |
Why?
|
| Young Adult | 2 | 2020 | 22059 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2019 | 9078 | 0.060 |
Why?
|
| Trastuzumab | 1 | 2007 | 736 | 0.060 |
Why?
|
| Animals | 7 | 2022 | 62771 | 0.050 |
Why?
|
| Quality Control | 1 | 2004 | 466 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2014 | 3067 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 5324 | 0.050 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2014 | 1913 | 0.050 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 2168 | 0.050 |
Why?
|
| Specimen Handling | 1 | 2004 | 311 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2020 | 4983 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2004 | 491 | 0.050 |
Why?
|
| HCT116 Cells | 1 | 2022 | 354 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 15253 | 0.050 |
Why?
|
| Male | 5 | 2020 | 128454 | 0.050 |
Why?
|
| Microarray Analysis | 2 | 2012 | 396 | 0.050 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2022 | 16593 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 6172 | 0.040 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2021 | 272 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2022 | 388 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2021 | 553 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2020 | 33827 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2019 | 251 | 0.040 |
Why?
|
| Mitosis | 1 | 2021 | 690 | 0.040 |
Why?
|
| Clone Cells | 1 | 2020 | 592 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 2 | 2012 | 4510 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2019 | 4067 | 0.040 |
Why?
|
| Acrylonitrile | 1 | 2017 | 9 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2022 | 887 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 1369 | 0.040 |
Why?
|
| Mutation | 3 | 2021 | 15854 | 0.040 |
Why?
|
| Mice, Inbred BALB C | 1 | 2022 | 2474 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2019 | 1089 | 0.030 |
Why?
|
| Survival Rate | 3 | 2020 | 12516 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2019 | 577 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2019 | 1046 | 0.030 |
Why?
|
| International Agencies | 1 | 2016 | 106 | 0.030 |
Why?
|
| Wnt Signaling Pathway | 1 | 2019 | 443 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2017 | 206 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 2368 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 1567 | 0.030 |
Why?
|
| Cadherins | 1 | 2019 | 677 | 0.030 |
Why?
|
| Genes, erbB-1 | 2 | 2006 | 103 | 0.030 |
Why?
|
| CTLA-4 Antigen | 1 | 2019 | 667 | 0.030 |
Why?
|
| Pathologists | 1 | 2016 | 101 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1820 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2019 | 1014 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2021 | 5834 | 0.030 |
Why?
|
| Genes, myc | 2 | 2006 | 373 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 368 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 3542 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2019 | 1004 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2011 | 2490 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2017 | 513 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2021 | 5108 | 0.030 |
Why?
|
| Cyclin D1 | 2 | 2005 | 589 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2012 | 252 | 0.030 |
Why?
|
| Androgens | 1 | 2015 | 558 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 1069 | 0.030 |
Why?
|
| Caspases, Initiator | 1 | 2011 | 17 | 0.030 |
Why?
|
| Bcl-2-Like Protein 11 | 1 | 2011 | 69 | 0.020 |
Why?
|
| Genotype | 1 | 2019 | 4109 | 0.020 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2012 | 297 | 0.020 |
Why?
|
| Arachidonic Acid | 1 | 2011 | 119 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2021 | 14679 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2017 | 1571 | 0.020 |
Why?
|
| Genomics | 1 | 2021 | 2817 | 0.020 |
Why?
|
| Protein Folding | 1 | 2011 | 300 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2012 | 257 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2011 | 725 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 5161 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 623 | 0.020 |
Why?
|
| Fatty Acids | 1 | 2011 | 448 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 1338 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 774 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2020 | 9433 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2019 | 39694 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2012 | 2109 | 0.020 |
Why?
|
| Cyclin D | 1 | 2006 | 40 | 0.020 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2006 | 118 | 0.020 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 2006 | 126 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2014 | 4002 | 0.020 |
Why?
|
| Switzerland | 1 | 2005 | 25 | 0.020 |
Why?
|
| Saudi Arabia | 1 | 2005 | 47 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2014 | 2198 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2014 | 2029 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2011 | 1645 | 0.020 |
Why?
|
| Cyclins | 1 | 2006 | 470 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 4985 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 3416 | 0.010 |
Why?
|
| Protein Array Analysis | 1 | 2006 | 505 | 0.010 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 2452 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2021 | 12206 | 0.010 |
Why?
|
| Risk Factors | 1 | 2019 | 17824 | 0.010 |
Why?
|
| Gene Dosage | 1 | 2004 | 827 | 0.010 |
Why?
|
| Epithelium | 1 | 2004 | 805 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 6248 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2011 | 2953 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 10250 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2005 | 843 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2006 | 1589 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2004 | 1961 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 7783 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2004 | 2351 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 4331 | 0.010 |
Why?
|
| ErbB Receptors | 1 | 2005 | 2379 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2014 | 7936 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2006 | 9307 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2004 | 3459 | 0.010 |
Why?
|
| DNA-Binding Proteins | 1 | 2006 | 5042 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2005 | 5438 | 0.010 |
Why?
|